Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicenter, open-label, randomized trial
Tuttle KR et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30104-9
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.